Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Barinthus Biotherapeutics plc - American Depositary Shares (NQ:BRNS)

0.8500 -0.0940 (-9.96%)
Streaming Delayed Price Updated: 3:56 PM EDT, May 19, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 46,589
Open 0.9200
Bid (Size) 0.7000 (6)
Ask (Size) 0.9500 (2)
Prev. Close 0.9440
Today's Range 0.8500 - 0.9200
52wk Range 0.6400 - 2.440
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Barinthus Bio Reports First Quarter 2025 Financial Results and Updates on Corporate Developments
From Barinthus Biotherapeutics
Via GlobeNewswire
Barinthus Bio Reports Full Year 2024 Financial Results and Updates on Corporate Developments
From Barinthus Biotherapeutics
Via GlobeNewswire

Performance

YTD
-31.5%
-31.5%
1 Month
+19.7%
+19.7%
3 Month
-21.3%
-21.3%
6 Month
+1.5%
+1.5%
1 Year
-64.6%
-64.6%

More News

Read More
Q1 Virtual Investor Summit: On-Demand Presentations Now Live
Via ACCESS Newswire
Barinthus Biotherapeutics plc to Present at the Investor Summit Virtual on March 11
Via ACCESS Newswire
Barinthus Bio Announces Strategic Focus in Immunology and Inflammation (I&I) and Provides a Financial Update
From Barinthus Biotherapeutics
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Barinthus Bio Promotes SNAP-TI Co-inventor, Geoffrey Lynn, M.D., Ph.D. to Chief Scientific Officer
From Barinthus Biotherapeutics
Via GlobeNewswire
Barinthus Bio Announces Results From Ongoing Phase 2b Chronic Hepatitis B Trial, Including Achievement of Functional Cure and HBsAb Seroconversion
From Barinthus Biotherapeutics
Via GlobeNewswire
Arbutus and Barinthus Bio Announce New Data from the IM-PROVE II Trial Showing that the Addition of Nivolumab Increased Rates of HBsAg Loss in People with Chronic Hepatitis B
From Barinthus Biotherapeutics
Via GlobeNewswire
Barinthus Bio Reports Third Quarter 2024 Update on Corporate Developments and Financial Results
From Barinthus Biotherapeutics
Via GlobeNewswire
Barinthus Bio Announces Late Breaking Presentation at AASLD 2024 – The Liver Meeting® and Attendance at November Conferences
From Barinthus Biotherapeutics
Via GlobeNewswire
Barinthus Bio Completes Enrollment for Phase 2b HBV003 Clinical Trial in Chronic Hepatitis B and Phase 1 PCA001 Clinical Trial in Prostate Cancer
From Barinthus Biotherapeutics
Via GlobeNewswire
Barinthus Bio Initiates Phase 1 Clinical Trial of VTP-1000 for the Treatment of Celiac Disease
From Barinthus Biotherapeutics
Via GlobeNewswire
BRNS Stock Earnings: Barinthus Biotherapeutics Misses EPS for Q2 2024
Via InvestorPlace
Barinthus Bio Reports Second Quarter 2024 Update on Corporate Developments and Financial Results
From Barinthus Biotherapeutics
Via GlobeNewswire
Sagimet Biosciences Announces Appointment of Anne Phillips and Jennifer Jarrett to its Board of Directors
From Sagimet Biosciences Inc.
Via GlobeNewswire
Why Sarepta Therapeutics Shares Are Trading Higher By Around 35%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Barinthus Bio Announces Strategic Pipeline Prioritization Following Positive Interim Data from VTP-300 in Chronic Hepatitis B Virus Infections
From Barinthus Biotherapeutics
Via GlobeNewswire
Barinthus Bio's VTP-300 Trials Demonstrate Ability to Achieve Undetectable HBsAg levels and Statistical Significance in Lowering HBsAg Levels in People with Chronic Hepatitis B
From Barinthus Biotherapeutics
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Barinthus Bio to Present VTP-300 Clinical Data Updates at EASL Congress 2024
From Barinthus Biotherapeutics
Via GlobeNewswire
BRNS Stock Earnings: Barinthus Biotherapeutics Beats EPS for Q1 2024
Via InvestorPlace
Barinthus Bio Reports First Quarter 2024 Financial Results and Update on Corporate Developments
From Barinthus Biotherapeutics
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Barinthus Bio Names Experienced Physician, Leon Hooftman, M.D., as Chief Medical Officer
From Barinthus Biotherapeutics
Via GlobeNewswire

Frequently Asked Questions

Is Barinthus Biotherapeutics plc - American Depositary Shares publicly traded?
Yes, Barinthus Biotherapeutics plc - American Depositary Shares is publicly traded.
What exchange does Barinthus Biotherapeutics plc - American Depositary Shares trade on?
Barinthus Biotherapeutics plc - American Depositary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for Barinthus Biotherapeutics plc - American Depositary Shares?
The ticker symbol for Barinthus Biotherapeutics plc - American Depositary Shares is BRNS on the Nasdaq Stock Market
What is the current price of Barinthus Biotherapeutics plc - American Depositary Shares?
The current price of Barinthus Biotherapeutics plc - American Depositary Shares is 0.8500
When was Barinthus Biotherapeutics plc - American Depositary Shares last traded?
The last trade of Barinthus Biotherapeutics plc - American Depositary Shares was at 05/19/25 03:56 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.